M Guarene1, A Pasi1, V Bolcato2, R Cananzi2, A Piccolo3, I Sbarsi1, C Klersy4, R Cacciatore1, Valeria Brazzelli5. 1. Immunogenetics Laboratory, Immunohematology and Transfusion Centre, IRCCS Policlinico San Matteo Foundation, University of Pavia, Pavia, Italy. 2. Institute of Dermatology, IRCCS Policlinico San Matteo Foundation, University of Pavia, Piazzale Golgi, 2, 27100, Pavia, Italy. 3. Unit of Anatomic Pathology, Department of Molecular Medicine, IRCCS Policlinico San Matteo Foundation, University of Pavia, Pavia, Italy. 4. Clinical Epidemiology and Biometric Unit, IRCCS Policlinico San Matteo Foundation, University of Pavia, Pavia, Italy. 5. Institute of Dermatology, IRCCS Policlinico San Matteo Foundation, University of Pavia, Piazzale Golgi, 2, 27100, Pavia, Italy. vbrazzelli@libero.it.
Abstract
BACKGROUND: Psoriasis is an immune-mediated dermatosis with a wide genetic predisposition. The immunogenetic background, specifically interactions between human leukocyte antigen (HLA) class I ligands and killer-cell immunoglobulin-like receptor (KIRs), have functional significance in modulating natural killer (NK) cells and can influence susceptibility and response to biological therapy. OBJECTIVE: The main aim of this study was to correlate HLA-A and -B KIR ligands with response to biological therapy in patients with psoriasis. METHODS: HLA-A and -B polymorphisms were determined in 48 patients (35 males and 13 females), with a mean of 22 years of disease (range 8-55). All patients were treated with biological therapy (adalimumab, etanercept, infliximab, or ustekinumab) for at least 6 months. RESULTS: This study identifies, with statistical significance, the presence of at least one ligand HLA-A Bw4-80I in the "poor-responder" population (patients who needed two or more biologics) compared with the "responder" population (patients with good response after a single biological drug) (47.62 vs. 11.11%; p = 0.006) as well as in "non-responders to etanercept" compared with "responders to etanercept" (52.63 vs. 5%; p = 0.001). CONCLUSION: Our preliminary results suggest that at least one ligand HLA-A Bw4-80I could be associated with "difficult-to-treat" psoriasis and that this ligand may reduce the probability of response to etanercept, producing more tumor necrosis factor (TNF)-α and neutralizing NK activity through a predominance of activating KIR. The ab initio identification of genetic markers of response to biologic therapy could improve the efficacy and economic impact of these agents.
BACKGROUND:Psoriasis is an immune-mediated dermatosis with a wide genetic predisposition. The immunogenetic background, specifically interactions between human leukocyte antigen (HLA) class I ligands and killer-cell immunoglobulin-like receptor (KIRs), have functional significance in modulating natural killer (NK) cells and can influence susceptibility and response to biological therapy. OBJECTIVE: The main aim of this study was to correlate HLA-A and -BKIR ligands with response to biological therapy in patients with psoriasis. METHODS:HLA-A and -B polymorphisms were determined in 48 patients (35 males and 13 females), with a mean of 22 years of disease (range 8-55). All patients were treated with biological therapy (adalimumab, etanercept, infliximab, or ustekinumab) for at least 6 months. RESULTS: This study identifies, with statistical significance, the presence of at least one ligand HLA-A Bw4-80I in the "poor-responder" population (patients who needed two or more biologics) compared with the "responder" population (patients with good response after a single biological drug) (47.62 vs. 11.11%; p = 0.006) as well as in "non-responders to etanercept" compared with "responders to etanercept" (52.63 vs. 5%; p = 0.001). CONCLUSION: Our preliminary results suggest that at least one ligand HLA-A Bw4-80I could be associated with "difficult-to-treat" psoriasis and that this ligand may reduce the probability of response to etanercept, producing more tumor necrosis factor (TNF)-α and neutralizing NK activity through a predominance of activating KIR. The ab initio identification of genetic markers of response to biologic therapy could improve the efficacy and economic impact of these agents.
Authors: A Nast; P Gisondi; A D Ormerod; P Saiag; C Smith; P I Spuls; P Arenberger; H Bachelez; J Barker; E Dauden; E M de Jong; E Feist; A Jacobs; R Jobling; L Kemény; M Maccarone; U Mrowietz; K A Papp; C Paul; K Reich; S Rosumeck; T Talme; H B Thio; P van de Kerkhof; R N Werner; N Yawalkar Journal: J Eur Acad Dermatol Venereol Date: 2015-10-19 Impact factor: 6.166
Authors: Philip E Stuart; Rajan P Nair; Lam C Tsoi; Trilokraj Tejasvi; Sayantan Das; Hyun Min Kang; Eva Ellinghaus; Vinod Chandran; Kristina Callis-Duffin; Robert Ike; Yanming Li; Xiaoquan Wen; Charlotta Enerbäck; Johann E Gudjonsson; Sulev Kõks; Külli Kingo; Tõnu Esko; Ulrich Mrowietz; Andre Reis; H Erich Wichmann; Christian Gieger; Per Hoffmann; Markus M Nöthen; Juliane Winkelmann; Manfred Kunz; Elvia G Moreta; Philip J Mease; Christopher T Ritchlin; Anne M Bowcock; Gerald G Krueger; Henry W Lim; Stephan Weidinger; Michael Weichenthal; John J Voorhees; Proton Rahman; Peter K Gregersen; Andre Franke; Dafna D Gladman; Gonçalo R Abecasis; James T Elder Journal: Am J Hum Genet Date: 2015-11-28 Impact factor: 11.025
Authors: Teresa María Linares-Pineda; Marisa Cañadas-Garre; Antonio Sánchez-Pozo; Miguel Ángel Calleja-Hernández Journal: Pharmacol Res Date: 2016-08-12 Impact factor: 7.658
Authors: C H Smith; Z K Jabbar-Lopez; Z Z Yiu; T Bale; A D Burden; L C Coates; M Cruickshank; T Hadoke; E MacMahon; R Murphy; C Nelson-Piercy; C M Owen; R Parslew; E Peleva; E Pottinger; E J Samarasekera; J Stoddart; C Strudwicke; V A Venning; R B Warren; L S Exton; M F Mohd Mustapa Journal: Br J Dermatol Date: 2017-09 Impact factor: 9.302
Authors: Haider H Zalzala; Galawish A Abdullah; Mohammed Y Abbas; Hyam R Mohammedsalih; Batool M Mahdi Journal: Saudi Med J Date: 2018-09 Impact factor: 1.484